Complete Genomics Raises IPO Target to $96.6M | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Complete Genomics today raised the total offering for its proposed initial public offering to as much as $96.6 million from its original goal of $86.3 million.

In an amended S-1 form filed with the US Securities and Exchange Commission, the Mountain View, Calif., sequencing services firm also reported preliminary earnings for the quarter ended Sept. 30.

For its IPO, Complete Genomics plans to offer 6 million shares at a share price between $12 and $14.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.